Now showing items 1-10 of 68
Cost of innovation in the pharmaceutical industry.
(J Health Econ, 1991-07)
The research and development costs of 93 randomly selected new chemical entities (NCEs) were obtained from a survey of 12 U.S.-owned pharmaceutical firms. These data were used to estimate the pre-tax average cost of new ...
R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
(International Journal of the Economics of Business, 1995-01-01)
This study examines the relationships between firm size, R&D costs and output in the pharmaceutical industry. Project-level data from a survey of 12 US-owned pharmaceutical firms on drug development costs, development phase ...
Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.
(Cancer Prev Res (Phila), 2008-07)
Chemoprevention agents are an emerging new scientific area that holds out the promise of delaying or avoiding a number of common cancers. These new agents face significant scientific, regulatory, and economic barriers, however, ...
Follow-on biologics: data exclusivity and the balance between innovation and competition
(Nature Reviews Drug Discovery, 2008-06)
Generic Competition in the U.S. Pharmaceutical Industry
(International Journal of the Economics of Business, 2006-02)
Do Faster FDA Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act
times have significantly declined since the passage of PDUFA in 1992, while agency resources have expanded through user fees. After the recent withdrawal of Vioxx and other high-profile products, there have been increasing ...
Do faster food and drug administration drug reviews adversely affect patient safety? An analysis of the 1992 prescription drug user fee act
(Journal of Law and Economics, 2008-05-01)
Food and Drug Administration (FDA) review times have significantly declined under the user-fee regime. This situation has provoked concerns that drug safety has been adversely affected. Combining information from several ...
Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
(Health Aff (Millwood), 2014-06)
In March 2010 Congress established an abbreviated Food and Drug Administration approval pathway for biosimilars-drugs that are very similar but not identical to a reference biological product and cost less. Because bringing ...
The cost of biopharmaceutical R&D: Is biotech different?
(Managerial and Decision Economics, 2007-06-01)
The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical firms have been estimated in a number of studies. However, similar analyses have not been published on the costs of developing ...